Scarica l'app Stockscreener
5.06
3.25%
-0.17
Dopo l'orario di chiusura:
5.06
Precedente Chiudi:
$5.23
Aprire:
$5.2
Volume 24 ore:
1.09M
Relative Volume:
0.56
Capitalizzazione di mercato:
$503.20M
Reddito:
$98.99M
Utile/perdita netta:
$-197.98M
Rapporto P/E:
-2.5279
EPS:
-2.0017
Flusso di cassa netto:
$-175.32M
1 W Prestazione:
-10.76%
1M Prestazione:
-14.38%
6M Prestazione:
-42.89%
1 anno Prestazione:
-51.81%
Intervallo 1D:
$5.02
$5.22
Intervallo di 1 settimana:
$5.02
$5.70
Portata 52W:
$4.9102
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
5.06 | 520.11M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Northland Capital | Outperform |
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire
רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRY - GlobeNewswire Inc.
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pha - The National Law Review
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - PR Newswire
Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Have Until October 5, 2026 to Seek a Lead Plaintiff Role - newmediawire.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
SPRY Should I Buy - Intellectia AI
ROSEN, A TOP RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - ACCESS Newswire
Another ARS Pharma (NASDAQ: SPRY) insider stock sale is coming, with the size now disclosed - Stock Titan
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire
ARS Pharmaceuticals (SPRY) insider lines up Sept. 3 stock sale after August trades - Stock Titan
Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors t - The National Law Review
SPRY UPCOMING DEADLINE: SueWallSt Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Chief commercial officer at ARS Pharma (SPRY) gets 1.0M stock options - Stock Titan
Insider at ARS Pharmaceuticals (NASDAQ: SPRY) plans another stock sale - Stock Titan
ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc. - TMX Newsfile
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact Levi & Korsinsky - PR Newswire
ARS Pharmaceuticals (SPRY) Institutional Ownership 2026 $SPRY - marketbeat.com
Kaplan Fox Continues to Alert Investors of a Securities Class Act - The National Law Review
Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on October 5, 2026 Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) - NewMediaWire
Repeat insider selling at ARS Pharma (SPRY) now includes a planned early-September trade - Stock Titan
Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
ARS Pharma (NASDAQ: SPRY) insider lines up new sale after August stock disposals - Stock Titan
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities - GlobeNewswire
SPRY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharma - The National Law Review
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel ... - Herald and News
Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026 - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. - globenewswire.com
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. LawsuitSPRY - Morningstar
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Inv - The National Law Review
Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire
ROSEN, NATIONAL TRIAL COUNSEL, Encourages ARS - GlobeNewswire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Hub ... - Herald and News
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026 - Barchart.com
Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Roblox Corporation (NYSE: RBLX); Symbotic Inc. (NASDAQ: SYM); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Cla - GlobeNewswire
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share - Yahoo Finance
SPRY Investors Have Rights – If You Lost Money Investing in - GlobeNewswire
ARS Pharmaceuticals, Inc. (SPRY) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):